Stock AnalizBausch Health Companies Inc. BHC
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Bausch Health Companies Inc. (BHC) is a healthcare company listed in the US with a market value of about $3.1B. In the twelve months to September 30, 2026 it had revenue of $11.1B and net income of -$841M, a net margin of -7.6%.
Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is value (2/5); the weakest is track record (0/5).
Key numbers: a price to free cash flow of 1.7, 5-year revenue growth of 5% a year, a 5-year average ROIC of 4%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 9% above the current price.
Score: 1.4 / 5
Checks passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- Profit margin improving
- Strong R&D investment or growth above 20%
- Positive free cash flow
- Interest covered more than 5 times
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.1B | $10.3B | $9.6B | $8.8B | $8.1B | $8.4B | $8.0B | $8.6B | $8.4B | $8.7B | $9.7B |
| Net income | -$841M | $157M | -$46M | -$592M | -$225M | -$948M | -$560M | -$1.8B | -$4.1B | $2.4B | -$2.4B |
| Free cash flow | $1.9B | $1.0B | $1.3B | $817M | -$946M | $1.2B | $809M | $1.2B | $1.3B | $2.1B | $1.9B |
| EPS (diluted) | $-2.29 | $0.42 | $-0.13 | $-1.62 | $-0.62 | $-2.64 | $-1.58 | $-5.08 | $-11.81 | $6.83 | $-6.94 |
| Net margin | -7.6% | 1.5% | -0.5% | -6.8% | -2.8% | -11.2% | -7.0% | -20.8% | -49.5% | 27.6% | -24.9% |
| ROIC | — | 7.0% | 5.9% | 3.5% | 1.8% | 1.8% | 1.6% | -0.7% | -8.7% | 0.3% | -1.7% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 5 analysts is $8.40, 1% above the current price; targets range from $7.00 to $10.00; the consensus rating is “Hold”; expected EPS is $4.91 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Bausch Health Companies stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 9% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Bausch Health Companies pay a dividend?
Not currently.
Is Bausch Health Companies a good stock to buy?
We do not give buy or sell advice. Bausch Health Companies scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.